Century Therapeutics Inc has a consensus price target of $16.44, established from looking at the 35 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, HC Wainwright & Co., and HC Wainwright & Co. on June 17, 2024, June 4, 2024, and May 10, 2024. With an average price target of $11.33 between Piper Sandler, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 392.75% upside for Century Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/17/2024 | Buy Now | 421.74% | Piper Sandler | Edward Tenthoff | $9 → $12 | Maintains | Overweight | Get Alert |
06/04/2024 | Buy Now | 378.26% | HC Wainwright & Co. | Mitchell Kapoor | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
05/10/2024 | Buy Now | 378.26% | HC Wainwright & Co. | Mitchell Kapoor | $13 → $11 | Maintains | Buy | Get Alert |
04/12/2024 | Buy Now | 291.3% | Piper Sandler | Edward Tenthoff | $10 → $9 | Reiterates | Overweight → Overweight | Get Alert |
03/15/2024 | Buy Now | 943.48% | Canaccord Genuity | Bill Maughan | $22 → $24 | Maintains | Buy | Get Alert |
03/15/2024 | Buy Now | 465.22% | HC Wainwright & Co. | Mitchell Kapoor | → $13 | Reiterates | Buy → Buy | Get Alert |
12/07/2023 | Buy Now | 465.22% | HC Wainwright & Co. | Mitchell Kapoor | → $13 | Reiterates | Buy → Buy | Get Alert |
08/28/2023 | Buy Now | 117.39% | JP Morgan | Eric Joseph | $28 → $5 | Downgrade | Overweight → Neutral | Get Alert |
08/10/2023 | Buy Now | 334.78% | Piper Sandler | Edward Tenthoff | $14 → $10 | Maintains | Overweight | Get Alert |
08/10/2023 | Buy Now | 465.22% | HC Wainwright & Co. | Mitchell Kapoor | $17 → $13 | Maintains | Buy | Get Alert |
08/10/2023 | Buy Now | 595.65% | EF Hutton | Tony Butler | → $16 | Reiterates | Buy → Buy | Get Alert |
08/10/2023 | Buy Now | 639.13% | Chardan Capital | Geulah Livshits | $19 → $17 | Maintains | Buy | Get Alert |
05/12/2023 | Buy Now | 639.13% | HC Wainwright & Co. | Mitchell Kapoor | → $17 | Reiterates | Buy → Buy | Get Alert |
04/17/2023 | Buy Now | 595.65% | EF Hutton | Tony Butler | → $16 | Maintains | Buy | Get Alert |
04/13/2023 | Buy Now | 639.13% | HC Wainwright & Co. | Mitchell Kapoor | → $17 | Reiterates | → Buy | Get Alert |
03/22/2023 | Buy Now | 726.09% | Chardan Capital | Geulah Livshits | → $19 | Reiterates | → Buy | Get Alert |
03/17/2023 | Buy Now | 639.13% | HC Wainwright & Co. | Mitchell Kapoor | $19 → $17 | Maintains | Buy | Get Alert |
03/16/2023 | Buy Now | 595.65% | EF Hutton | Tony Butler | → $16 | Reiterates | → Buy | Get Alert |
02/09/2023 | Buy Now | 726.09% | HC Wainwright & Co. | Mitchell Kapoor | → $19 | Reiterates | → Buy | Get Alert |
01/06/2023 | Buy Now | 595.65% | EF Hutton | Tony Butler | $18 → $16 | Maintains | Buy | Get Alert |
01/06/2023 | Buy Now | 508.7% | SVB Leerink | Daina Graybosch | $20 → $14 | Maintains | Outperform | Get Alert |
01/06/2023 | Buy Now | 508.7% | Piper Sandler | Edward Tenthoff | $24 → $14 | Maintains | Overweight | Get Alert |
01/06/2023 | Buy Now | 726.09% | HC Wainwright & Co. | Mitchell Kapoor | $25 → $19 | Maintains | Buy | Get Alert |
01/05/2023 | Buy Now | 682.61% | EF Hutton | Tony Butler | → $18 | Initiates | → Buy | Get Alert |
12/27/2022 | Buy Now | 726.09% | Chardan Capital | Geulah Livshits | → $19 | Initiates | → Buy | Get Alert |
11/14/2022 | Buy Now | 986.96% | HC Wainwright & Co. | Mitchell Kapoor | $27 → $25 | Maintains | Buy | Get Alert |
10/31/2022 | Buy Now | 552.17% | Guggenheim | Kelsey Goodwin | → $15 | Initiates | → Buy | Get Alert |
05/23/2022 | Buy Now | 1073.91% | HC Wainwright & Co. | Mitchell Kapoor | → $27 | Initiates | → Buy | Get Alert |
05/17/2022 | Buy Now | 856.52% | Piper Sandler | Edward Tenthoff | $38 → $22 | Maintains | Overweight | Get Alert |
04/29/2022 | Buy Now | 1073.91% | SVB Leerink | Daina Graybosch | $32 → $27 | Maintains | Outperform | Get Alert |
11/19/2021 | Buy Now | 1291.3% | SVB Leerink | Daina Graybosch | — | Maintains | Outperform | Get Alert |
07/13/2021 | Buy Now | 1378.26% | B of A Securities | Geoff Meacham | — | Initiates | → Buy | Get Alert |
07/13/2021 | Buy Now | 1334.78% | SVB Leerink | Daina Graybosch | — | Initiates | → Outperform | Get Alert |
07/13/2021 | Buy Now | 1639.13% | JP Morgan | Eric Joseph | — | Initiates | → Overweight | Get Alert |
07/13/2021 | Buy Now | 1552.17% | Piper Sandler | Edward Tenthoff | — | Initiates | → Overweight | Get Alert |
The latest price target for Century Therapeutics (NASDAQ:IPSC) was reported by Piper Sandler on June 17, 2024. The analyst firm set a price target for $12.00 expecting IPSC to rise to within 12 months (a possible 421.74% upside). 12 analyst firms have reported ratings in the last year.
The latest analyst rating for Century Therapeutics (NASDAQ:IPSC) was provided by Piper Sandler, and Century Therapeutics maintained their overweight rating.
There is no last upgrade for Century Therapeutics
The last downgrade for Century Therapeutics Inc happened on August 28, 2023 when JP Morgan changed their price target from $28 to $5 for Century Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Century Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Century Therapeutics was filed on June 17, 2024 so you should expect the next rating to be made available sometime around June 17, 2025.
While ratings are subjective and will change, the latest Century Therapeutics (IPSC) rating was a maintained with a price target of $9.00 to $12.00. The current price Century Therapeutics (IPSC) is trading at is $2.30, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.